Our findings also indicated that copeptin might be used as an auxiliary biomarker to differentiate ischemic stroke and hemorrhagic stroke in clinical application, which is crucial for the immediate application of the right therapy to patients. The gene discussed is AVP; the disease is ischemic stroke.